Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hermanski-Pudlak Syndrome | 7 | 2024 | 13 | 2.470 |
Why?
|
| Bivalvia | 9 | 2022 | 21 | 1.940 |
Why?
|
| Albinism, Oculocutaneous | 4 | 2024 | 6 | 1.770 |
Why?
|
| Hemoglobins | 11 | 2022 | 107 | 1.760 |
Why?
|
| Monophenol Monooxygenase | 3 | 2024 | 14 | 1.480 |
Why?
|
| Mutation | 11 | 2024 | 1095 | 1.240 |
Why?
|
| Repressor Proteins | 5 | 2021 | 249 | 1.220 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 39 | 0.890 |
Why?
|
| Carrier Proteins | 4 | 2018 | 305 | 0.730 |
Why?
|
| Puerto Rico | 16 | 2023 | 1378 | 0.700 |
Why?
|
| Heterozygote | 5 | 2024 | 93 | 0.690 |
Why?
|
| Warfarin | 8 | 2016 | 64 | 0.690 |
Why?
|
| Membrane Proteins | 3 | 2014 | 517 | 0.620 |
Why?
|
| Genetic Testing | 5 | 2024 | 75 | 0.620 |
Why?
|
| Evolution, Molecular | 2 | 2022 | 268 | 0.620 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 7 | 2015 | 52 | 0.600 |
Why?
|
| Histones | 1 | 2018 | 190 | 0.580 |
Why?
|
| Oxygen | 4 | 2022 | 207 | 0.580 |
Why?
|
| Sulfides | 2 | 2022 | 62 | 0.580 |
Why?
|
| RNA, Messenger | 5 | 2018 | 1207 | 0.560 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 9 | 0.550 |
Why?
|
| Anticoagulants | 8 | 2016 | 102 | 0.530 |
Why?
|
| Focal Dermal Hypoplasia | 2 | 2014 | 2 | 0.530 |
Why?
|
| Skin Diseases | 2 | 2014 | 31 | 0.520 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 78 | 0.510 |
Why?
|
| Iris Diseases | 1 | 2014 | 2 | 0.490 |
Why?
|
| Retinal Diseases | 1 | 2014 | 17 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 178 | 0.480 |
Why?
|
| Strabismus | 1 | 2014 | 17 | 0.480 |
Why?
|
| Hydrogen Sulfide | 4 | 2016 | 39 | 0.470 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2013 | 17 | 0.470 |
Why?
|
| Transcriptional Activation | 2 | 2011 | 172 | 0.470 |
Why?
|
| Vision Disorders | 1 | 2014 | 58 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 807 | 0.430 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 103 | 0.420 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 191 | 0.410 |
Why?
|
| Amino Acid Sequence | 9 | 2022 | 1180 | 0.410 |
Why?
|
| Humans | 33 | 2024 | 37093 | 0.410 |
Why?
|
| Mixed Function Oxygenases | 5 | 2012 | 34 | 0.400 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2011 | 13 | 0.400 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 336 | 0.400 |
Why?
|
| Base Sequence | 5 | 2018 | 997 | 0.390 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 75 | 0.380 |
Why?
|
| Hemoglobin, Sickle | 1 | 2010 | 13 | 0.380 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2010 | 5 | 0.380 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 578 | 0.360 |
Why?
|
| Erythrocytes | 1 | 2010 | 111 | 0.360 |
Why?
|
| Proteins | 1 | 2012 | 369 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 623 | 0.340 |
Why?
|
| Child | 7 | 2023 | 3131 | 0.330 |
Why?
|
| Ectodermal Dysplasia | 3 | 2021 | 5 | 0.330 |
Why?
|
| Escherichia coli | 3 | 2010 | 453 | 0.320 |
Why?
|
| Molecular Sequence Data | 7 | 2016 | 1568 | 0.320 |
Why?
|
| Poly A | 1 | 2008 | 33 | 0.310 |
Why?
|
| Folic Acid | 2 | 2011 | 46 | 0.300 |
Why?
|
| DNA, Complementary | 2 | 2008 | 191 | 0.300 |
Why?
|
| Pedigree | 3 | 2024 | 79 | 0.300 |
Why?
|
| Female | 18 | 2024 | 20969 | 0.300 |
Why?
|
| Hemorrhage | 2 | 2019 | 45 | 0.290 |
Why?
|
| Exons | 2 | 2018 | 88 | 0.280 |
Why?
|
| Male | 15 | 2024 | 20025 | 0.280 |
Why?
|
| Fibroblasts | 2 | 2021 | 272 | 0.250 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1015 | 0.250 |
Why?
|
| Homozygote | 5 | 2015 | 77 | 0.250 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 626 | 0.250 |
Why?
|
| Sequence Alignment | 5 | 2016 | 265 | 0.250 |
Why?
|
| Genotype | 7 | 2016 | 730 | 0.250 |
Why?
|
| Tyrosine | 3 | 2014 | 118 | 0.240 |
Why?
|
| Adult | 11 | 2024 | 11712 | 0.240 |
Why?
|
| Animals | 13 | 2022 | 15081 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 448 | 0.210 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2002 | 3 | 0.210 |
Why?
|
| Erythrocyte Volume | 1 | 2002 | 4 | 0.210 |
Why?
|
| Infant, Newborn | 5 | 2011 | 894 | 0.210 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2002 | 2 | 0.210 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 3 | 0.210 |
Why?
|
| Pharmacogenetics | 3 | 2015 | 49 | 0.210 |
Why?
|
| Cloning, Molecular | 4 | 2008 | 325 | 0.200 |
Why?
|
| Codon, Nonsense | 2 | 2011 | 21 | 0.190 |
Why?
|
| Incidence | 1 | 2023 | 922 | 0.180 |
Why?
|
| Computational Biology | 1 | 2022 | 293 | 0.180 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 95 | 0.180 |
Why?
|
| Hemeproteins | 2 | 2010 | 14 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 187 | 0.170 |
Why?
|
| Aged | 7 | 2016 | 6741 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2013 | 1418 | 0.170 |
Why?
|
| Phylogeny | 2 | 2022 | 644 | 0.170 |
Why?
|
| Wetlands | 1 | 2018 | 15 | 0.160 |
Why?
|
| Heme | 4 | 2009 | 70 | 0.160 |
Why?
|
| Conserved Sequence | 1 | 2018 | 119 | 0.160 |
Why?
|
| Aspergillus | 1 | 2018 | 9 | 0.160 |
Why?
|
| Antibodies, Fungal | 1 | 2018 | 23 | 0.160 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 92 | 0.160 |
Why?
|
| Antigens, Fungal | 1 | 2018 | 31 | 0.150 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 55 | 0.150 |
Why?
|
| Algorithms | 3 | 2016 | 465 | 0.150 |
Why?
|
| Mutation, Missense | 2 | 2015 | 83 | 0.150 |
Why?
|
| Allergens | 1 | 2018 | 63 | 0.150 |
Why?
|
| Mollusca | 2 | 2008 | 14 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 474 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 295 | 0.140 |
Why?
|
| Middle Aged | 8 | 2016 | 10129 | 0.140 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2016 | 29 | 0.140 |
Why?
|
| Blotting, Northern | 2 | 2008 | 150 | 0.130 |
Why?
|
| Visual Acuity | 2 | 2014 | 97 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2016 | 2026 | 0.130 |
Why?
|
| Thrombosis | 1 | 2016 | 63 | 0.130 |
Why?
|
| United States | 2 | 2023 | 4223 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2016 | 127 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 306 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2018 | 859 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 101 | 0.120 |
Why?
|
| Eye Color | 1 | 2014 | 3 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 93 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 75 | 0.120 |
Why?
|
| Adolescent | 5 | 2014 | 5363 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 515 | 0.110 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 29 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 108 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 131 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2012 | 26 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 189 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1039 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 767 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2010 | 307 | 0.100 |
Why?
|
| Malabsorption Syndromes | 1 | 2011 | 3 | 0.100 |
Why?
|
| Kinetics | 4 | 2006 | 708 | 0.100 |
Why?
|
| Reticulocyte Count | 1 | 2010 | 3 | 0.100 |
Why?
|
| Osteogenesis | 1 | 2010 | 35 | 0.090 |
Why?
|
| Neonatal Screening | 1 | 2010 | 25 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 36 | 0.090 |
Why?
|
| Immune System | 1 | 2010 | 41 | 0.090 |
Why?
|
| Muscle Development | 1 | 2010 | 45 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2011 | 103 | 0.090 |
Why?
|
| DNA | 2 | 2010 | 574 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2010 | 44 | 0.090 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2015 | 13 | 0.090 |
Why?
|
| Amino Acid Substitution | 3 | 2009 | 132 | 0.090 |
Why?
|
| Metagenomics | 1 | 2009 | 34 | 0.080 |
Why?
|
| Ferric Compounds | 2 | 2006 | 51 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 439 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2010 | 149 | 0.080 |
Why?
|
| Protein Binding | 3 | 2009 | 972 | 0.080 |
Why?
|
| Prognosis | 1 | 2010 | 739 | 0.080 |
Why?
|
| Fovea Centralis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Alleles | 2 | 2015 | 321 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 2379 | 0.080 |
Why?
|
| Ligands | 2 | 2005 | 349 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2015 | 195 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1518 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 628 | 0.070 |
Why?
|
| Binding Sites | 2 | 2010 | 651 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 706 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2006 | 87 | 0.070 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hemostatics | 1 | 2005 | 8 | 0.060 |
Why?
|
| Neurons | 1 | 2012 | 1175 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 98 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1398 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2004 | 158 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 188 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 132 | 0.060 |
Why?
|
| Codon | 1 | 2003 | 42 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 4268 | 0.060 |
Why?
|
| Temperature | 1 | 2004 | 286 | 0.060 |
Why?
|
| Prevalence | 3 | 2015 | 1455 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 689 | 0.050 |
Why?
|
| Infant | 1 | 2006 | 1046 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2002 | 12 | 0.050 |
Why?
|
| Alanine | 1 | 2002 | 30 | 0.050 |
Why?
|
| Valine | 1 | 2002 | 31 | 0.050 |
Why?
|
| Risk | 1 | 2002 | 267 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 1492 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 114 | 0.040 |
Why?
|
| Ferrous Compounds | 2 | 2009 | 20 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 89 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 260 | 0.040 |
Why?
|
| Pregnancy | 1 | 2002 | 1549 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 2 | 2009 | 88 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 448 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 3 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 54 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2016 | 69 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 175 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 661 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2005 | 68 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Crystallography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 88 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 22 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 91 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1130 | 0.030 |
Why?
|
| Hydrogen Peroxide | 2 | 2006 | 190 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 204 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2006 | 364 | 0.030 |
Why?
|
| Cystatin B | 1 | 2012 | 7 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2012 | 17 | 0.030 |
Why?
|
| Cystatin C | 1 | 2012 | 24 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 362 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2012 | 35 | 0.030 |
Why?
|
| Lysosomes | 1 | 2012 | 91 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2012 | 455 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 168 | 0.020 |
Why?
|
| Facies | 1 | 2010 | 4 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2010 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 74 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 188 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 257 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 111 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 35 | 0.020 |
Why?
|
| Electron Transport | 1 | 2009 | 40 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 57 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 167 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 68 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 561 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 398 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1378 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 195 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2007 | 7 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 409 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 22 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 933 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 808 | 0.020 |
Why?
|
| Cyanides | 1 | 2005 | 11 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 34 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2006 | 132 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2231 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2005 | 5 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 408 | 0.020 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 8 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2004 | 207 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 225 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 515 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 2721 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1369 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 5913 | 0.010 |
Why?
|